Cat. No.: HY-N1486

Ursonic acid

(Synonyms: 3-Ketoursolic acid)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Ursolic acid is a naturally occurring triterpenoid that has orally active. Ursolic acid induces the apoptosis of human cancer cells through multiple signaling pathways. Ursolic acid has anti-inflammatory and anticarcinogenic activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.88%
CAS No.: 6246-46-4
Formule: C₃₀H₄₆O₃
Masse moléculaire:454.68

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Ursonic acid Chemical Structure

CAS No.: 6246-46-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Endogenous Metabolite :

Voir tous les produits spécifiques à Isoform NF-κB :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	57 μM Compound: 16	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
A549	IC₅₀	>50 μM Compound: 7a	Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
A549	IC₅₀	15 μM Compound: 2	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26854375]
A549	IC₅₀	50 μM Compound: 5a	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
ASPC1	IC₅₀	24.5 μM Compound: 4	Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay	[PMID: 22959527]
BJ	IC₅₀	>50 μM Compound: 7a	Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
BJ	IC₅₀	>50 μM Compound: 5a	Cytotoxicity against human BJ cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human BJ cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
CCRF-CEM	IC₅₀	10.4 μM Compound: 7a	Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
CCRF-CEM	IC₅₀	16 μM Compound: 5a	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
CEM-DNR	IC₅₀	19 μM Compound: 5a	Cytotoxicity against human CEM-DNR cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human CEM-DNR cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
HCT-116	GI₅₀	5.3 μM Compound: 16	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
HCT-116	IC₅₀	>50 μM Compound: 7a	Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
HCT-116	IC₅₀	2.3 μM Compound: 2	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26854375]
HCT-116	IC₅₀	47 μM Compound: 5a	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
HCT-116	IC₅₀	49.7 μM Compound: 7a	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
HeLa	IC₅₀	>40 μM Compound: 2	Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28733083]
HepG2	CC₅₀	>400 μM Compound: 4a	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29326018]
HepG2	IC₅₀	>100 μM Compound: 2	Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25537271]
HL-60	IC₅₀	>40 μM Compound: 2	Growth inhibition of human HL60 cells after 48 hrs by MTT assay Growth inhibition of human HL60 cells after 48 hrs by MTT assay	[PMID: 28073673]
K562	IC₅₀	>50 μM Compound: 7a	Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
K562	IC₅₀	>50 μM Compound: 5a	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
MCF7	GI₅₀	12 μM Compound: 16	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32345458]
MCF7	IC₅₀	56 μM Compound: 2	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26854375]
MDA-MB-231	IC₅₀	>40 μM Compound: 2	Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28733083]
MRC5	IC₅₀	>50 μM Compound: 7a	Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
MRC5	IC₅₀	>50 μM Compound: 5a	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
NTUB1	IC₅₀	21.44 μM Compound: 18	Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay	[PMID: 19758808]
RAW264.7	IC₅₀	4.94 μM Compound: 2	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 28427811]
SMMC-7721	IC₅₀	>40 μM Compound: 2	Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 28733083]
THP-1	IC₅₀	13 μM Compound: 2	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 26854375]
U2OS	IC₅₀	>50 μM Compound: 7a	Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
U2OS	IC₅₀	>50 μM Compound: 5a	Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
Vero	CC₅₀	>400 μM Compound: 4a	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 29326018]
Vero	IC₅₀	2.5 μg/mL Compound: 5, ursonic acid	Antiviral activity against HSV1 MacIntyre replication in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against HSV1 MacIntyre replication in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 2828553]
Vero	IC₅₀	8 μg/mL Compound: 5, ursonic acid	Antiviral activity against HSV2 MS replication infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against HSV2 MS replication infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 2828553]

In Vitro

Ursolic acid (12.5-50 μM, 48 h) induce apoptosis in T24 human bladder cancer cells in a dose-dependent manner by inhibiting AKT/NF-κB signaling^[1].
Ursolic acid (50 μM, 2-4 h) increases the expression of p53 and caspase-3 and decreases bcl-2 gene expression in B16F-10 melanoma cells^[2].
Ursolic acid (10-50 μM, 48 h) inhibits the production of TNF-α, IL-1β, IL-6 and GM-CSF in B16F-10 melanoma cells^[2].
Ursolic acid (50 μM, 2 h) inhibits the NF-κB subunits (p65, p50 and c-Rel) and nuclear translocation of c-fos, ATF-2 and CREB-1 in B16F-10 melanoma cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

T24 human bladder cancer cells
Concentration:

12.5-50 μM
Incubation Time:

48 h
Result:

Inhibited cell proliferation in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:

T24 human bladder cancer cells
Concentration:

12.5-50 μM
Incubation Time:

48 h
Result:

Inhibited the anti-apoptotic signaling (pAkt1, pIκBα, NF-κBp65 and Bcl-2).
Activated pro-apoptotic signaling (caspase-3).

In Vivo

Ursolic acid (5-20 mg/kg, p.o., twice a day, 30 days) protects against ethanol-mediated experimental liver injury in adult male albino rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male albino rats^[3]
Dosage:

5-20 mg/kg
Administration:

p.o., twice a day, 30 days
Result:

Increased weight gain and food intake.
Decreased AST and ALT activities and total and indirect bilirubin levels.
Increased direct bilirubin and levels of non-enzymic antioxidants (GSH, ascorbic acid and a-tocopherol).
Decreased lipid peroxidation.

Chemical Information

CAS No. 6246-46-4
Appearance Solid
Masse moléculaire 454.68
Formule C₃₀H₄₆O₃
Color White to off-white
SMILES

CC1(C)C(CC[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H])=O
Synonyms

3-Ketoursolic acid
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- Rhamnaceae
- Endogenous metabolite
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 May 9:204:107208. PMID: 38729587

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (109.97 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1993 mL

10.9967 mL

21.9935 mL

5 mM

0.4399 mL

2.1993 mL

4.3987 mL

10 mM

0.2199 mL

1.0997 mL

2.1993 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Gai, L., Cai, N., Wang, L., Xu, X. & Kong, X. Ursolic acid induces apoptosis via Akt/NF-kappaB signaling suppression in T24 human bladder cancer cells. Molecular medicine reports 7, 1673-1677, doi:10.3892/mmr.2013.1364 (2013). [Content Brief]

[2]. Manu, K. A. & Kuttan, G. Ursolic acid induces apoptosis by activating p53 and caspase-3 gene expressions and suppressing NF-kappaB mediated activation of bcl-2 in B16F-10 melanoma cells. International immunopharmacology 8, 974-981, doi:10.1016/j.intimp.2008.02.013 (2008). [Content Brief]

[3]. Saravanan R, et al. Protective effect of ursolic acid on ethanol-mediated experimental liver damage in rats. Life Sci. 2006 Jan 11;78(7):713-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1993 mL	10.9967 mL	21.9935 mL	54.9837 mL
	5 mM	0.4399 mL	2.1993 mL	4.3987 mL	10.9967 mL
	10 mM	0.2199 mL	1.0997 mL	2.1993 mL	5.4984 mL
	15 mM	0.1466 mL	0.7331 mL	1.4662 mL	3.6656 mL
	20 mM	0.1100 mL	0.5498 mL	1.0997 mL	2.7492 mL
	25 mM	0.0880 mL	0.4399 mL	0.8797 mL	2.1993 mL
	30 mM	0.0733 mL	0.3666 mL	0.7331 mL	1.8328 mL
	40 mM	0.0550 mL	0.2749 mL	0.5498 mL	1.3746 mL
	50 mM	0.0440 mL	0.2199 mL	0.4399 mL	1.0997 mL
	60 mM	0.0367 mL	0.1833 mL	0.3666 mL	0.9164 mL
	80 mM	0.0275 mL	0.1375 mL	0.2749 mL	0.6873 mL
	100 mM	0.0220 mL	0.1100 mL	0.2199 mL	0.5498 mL

Keywords

Ursonic acid

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ursonic acid

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Marine-Sourced Natural Product Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Ursonic acid

Voir tous les produits spécifiques à Isoform Endogenous Metabolite

Voir tous les produits spécifiques à Isoform NF-κB

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Ursonic acid Related Classifications

HY-N1486 Related Classifications